Neue Medikamente in der Onkologie

详细信息    查看全文

• 作者：Prof. Dr. N.P. Malek (1)
  M. Bitzer (1)
  
• 关键词：Stammzellen ; c ; MET ; Signalweg ; Humanes CTLA4 ; Protein ; Epigenetik ; Onkolytische Virotherapie ; Stem cells ; c ; MET signaling ; CTLA4 protein ; human ; Epigenetics ; Oncolytic virotherapy
• 刊名：Der Internist
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：55
• 期：4
• 页码：359-366
• 全文大小：539 KB
• 参考文献：1. Andtbacka R (2013) A randomized phase聽III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage聽IIIB/C and IV melanoma. J聽Clin Oncol 31 (Suppl):Abstract LBA9008
  2. Bitzer M (2012) Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase聽II SHELTER study. J聽Clin Oncol 30
  3. Cooper CS, Park M, Blair DG et聽al (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29鈥?3 CrossRef
  4. Mello RA de, Marques AM, Araujo A (2013) Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies. World J Gastroenterol 19:6315鈥?318 CrossRef
  5. Di Renzo MF, Olivero M, Martone T et聽al (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547鈥?555 CrossRef
  6. Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808鈥?817 CrossRef
  7. Faivre S, Demetri G, Sargent W et聽al (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734鈥?45 CrossRef
  8. Gherardi E, Birchmeier W, Birchmeier C et聽al (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89鈥?03 CrossRef
  9. Graveel CR, DeGroot JD, Sigler RE et聽al (2010) Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One 5:e13586 CrossRef
  10. Heo J, Reid T, Ruo L et聽al (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19:329鈥?36 CrossRef
  11. Hodi FS, O鈥橠ay SJ, McDermott DF et聽al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N聽Engl J Med 363:711鈥?23
  12. Lauer U (2013) Phase聽I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresectable, chemotherapy-resistant peritoneal carcinomatosis. J聽Clin Oncol 31 (Suppl):3098
  13. Lonardo E, Hermann PC, Mueller MT et聽al (2011) Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9:433鈥?46 CrossRef
  14. Mueller MT, Hermann PC, Witthauer J et聽al (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137:1102鈥?113 CrossRef
  15. Nguyen LV, Vanner R, Dirks P et聽al (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133鈥?43
  16. Olsen EA, Kim YH, Kuzel TM et聽al (2007) Phase聽IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J聽Clin Oncol 25:3109鈥?115
  17. Patel MR, Kratzke RA (2013) Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 161:355鈥?64 CrossRef
  18. Phan GQ, Yang JC, Sherry RM et聽al (2003) Cancer regression and autoimmunity induced by cytotoxic T聽lymphocyte-associated antigen聽4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U聽S聽A 100:8372鈥?377 CrossRef
  19. Qiu T, Zhou L, Zhu W et聽al (2013) Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30聽clinical trials. Future Oncol 9:255鈥?69 CrossRef
  20. Rommelaere J, Geletneky K, Angelova AL et聽al (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 21:185鈥?95 CrossRef
  21. Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229:12鈥?6 CrossRef
  22. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:658鈥?70 CrossRef
  23. Santoro A, Rimassa L, Borbath I et聽al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase聽2 study. Lancet Oncol 14:55鈥?3 CrossRef
  24. Seshacharyulu P, Ponnusamy MP, Haridas D et聽al (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15鈥?1 CrossRef
  25. Timp W, Feinberg AP (2013) Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 13:497鈥?10 CrossRef
  26. Valent P, Bonnet D, De Maria R et聽al (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12:767鈥?75 CrossRef
  27. Elsas A van, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16聽melanoma using anti-cytotoxic T聽lymphocyte-associated antigen聽4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J聽Exp Med 190:355鈥?66
  28. Waterhouse P, Penninger JM, Timms E et聽al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985鈥?88 CrossRef
  29. Whittaker SJ, Demierre MF, Kim EJ et聽al (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J聽Clin Oncol 28:4485鈥?491
  30. Zender S, Nickeleit I, Wuestefeld T et聽al (2013) A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23:784鈥?95 CrossRef
  
• 作者单位：Prof. Dr. N.P. Malek (1)
  M. Bitzer (1)
  
  1. Medizinische Klinik 1 (Gastroenterologie, Hepatologie, Infektiologie), Universit盲tsklinikum T眉bingen, Otfried-M眉ller-Str. 10, 72076, T眉bingen, Deutschland
  
• ISSN：1432-1289

文摘

Background Drug development in oncology has seen major innovations in recent years. Based on the molecular changes found in malignant tumors, new drugs are being developed which specifically target these altered signaling pathways. Results In addition to the already broadly used inhibitors of growth factor and angiogenic signaling pathways, new and innovative target structures have been identified. Cancer stem cells which are thought to be the reason for drug resistance and tumor recurrence are now being targeted. c-MET signaling has emerged as an important new signaling module which can be influenced pharmacologically. Inhibitors of immune checkpoints like antibodies which target the CTLA4 molecule are leading to impressive results in clinical trials. Drugs which influence the epigentic changes found in tumor cells are tested specifically for their ability to overcome drug resistance. Finally, treatment with oncolytic viruses has made a comeback in certain tumor entities. Conclusion Oncological treatments will see a significant addition of new drugs and treatment options in the next few years which will hopefully improve the survival of patients with tumors.